{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:39:08Z","timestamp":1792791548471,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mcpiqojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings: Innovations, Quality &amp; Outcomes"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.mayocpiqo.2026.100758","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:16:51Z","timestamp":1790198211000},"page":"100758","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety Profile of Chimeric Antigen Receptor T-cell Therapies in Diffuse Large B-cell Lymphoma: An Analysis of Real-World Adverse Event Reporting From the FDA Adverse Event Reporting System"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9574-3496","authenticated-orcid":false,"given":"Magdi","family":"Elsallab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Lunning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moataz","family":"Ellithi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Toron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pearl","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxwell","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela V.","family":"Maus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.mayocpiqo.2026.100758_bib1","doi-asserted-by":"crossref","first-page":"118","DOI":"10.5858\/2008-132-118-DLBL","article-title":"Diffuse large B-cell lymphoma","volume":"132","author":"Hunt","year":"2008","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2026.100758_bib2","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.critrevonc.2012.12.009","article-title":"Diffuse large B-cell lymphoma","volume":"87","author":"Martelli","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"issue":"27","key":"10.1016\/j.mayocpiqo.2026.100758_bib3","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"issue":"suppl 3","key":"10.1016\/j.mayocpiqo.2026.100758_bib7","first-page":"21","article-title":"CAR T-cell therapy: adverse events and management","volume":"10","author":"Adkins","year":"2019","journal-title":"J Adv Pract Oncol"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2026.100758_bib8","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.mayocpiqo.2026.100758_bib9","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1200\/JCO.20.01134","article-title":"Early off-study experience of chimeric antigen receptor T cells in aggressive lymphoma: closer to a real-world setting","volume":"38","author":"Ghesquieres","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.mayocpiqo.2026.100758_bib10","doi-asserted-by":"crossref","first-page":"581.e1","DOI":"10.1016\/j.jtct.2022.05.026","article-title":"Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States","volume":"28","author":"Jacobson","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2026.100758_bib11","doi-asserted-by":"crossref","first-page":"77.e1","DOI":"10.1016\/j.jtct.2023.10.017","article-title":"Real-world outcomes with chimeric antigen receptor T cell therapies in large B cell lymphoma: a systematic review and meta-analysis","volume":"30","author":"Jacobson","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2026.100758_bib13","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3390\/healthcare10030420","article-title":"A standardized dataset of a spontaneous adverse event reporting system","volume":"10","author":"Khaleel","year":"2022","journal-title":"Healthcare (Basel)"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2026.100758_bib15","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1182\/bloodadvances.2024012992","article-title":"A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma","volume":"9","author":"Looka","year":"2025","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2026.100758_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2023.12.249","article-title":"Real-world comparison of lisocabtagene maraleucel (liso-cel) and axicabtagene ciloleucel (axi-cel): efficacy & toxicity","volume":"30","author":"Portuguese","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2026.100758_bib17","doi-asserted-by":"crossref","first-page":"S392","DOI":"10.1016\/j.jtct.2025.01.604","article-title":"Post market analysis of toxicities reported with chimeric antigen receptor (CAR) T-cell therapies and bispecific T-cell engager (BiTE) for diffuse large B-cell lymphoma (DLBCL) using the FDA Adverse Event Reporting System (FAERS)","volume":"31","author":"Giese","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"10.1016\/j.mayocpiqo.2026.100758_bib18","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s40264-022-01194-z","article-title":"Post-marketing surveillance of CAR-T-cell therapies: analysis of the FDA Adverse Event Reporting System (FAERS) database","volume":"45","author":"Fusaroli","year":"2022","journal-title":"Drug Saf"},{"issue":"suppl 1","key":"10.1016\/j.mayocpiqo.2026.100758_bib19","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1182\/blood-2022-160216","article-title":"Matching-adjusted indirect comparison (MAIC) of lisocabtagene maraleucel (liso-cel) versus axicabtagene ciloleucel (axi-cel) for second-line (2L) treatment of patients (Pt) with refractory\/early relapsed (R\/R) large B-cell lymphoma (LBCL)","volume":"140","author":"Abramson","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2026.100758_bib20","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13045-021-01144-9","article-title":"Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma","volume":"14","author":"Maloney","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"13","key":"10.1016\/j.mayocpiqo.2026.100758_bib21","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1080\/10428194.2022.2113526","article-title":"Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma","volume":"63","author":"Oluwole","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.mayocpiqo.2026.100758_bib22","first-page":"1","article-title":"Anticytokine therapy and corticosteroids for cytokine release syndrome and for neurotoxicity following T-cell engager or CAR T-cell therapy","volume":"4","year":"2024","journal-title":"Can J Health Technol"},{"issue":"7","key":"10.1016\/j.mayocpiqo.2026.100758_bib23","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s40264-025-01538-5","article-title":"Mitigation and management of common toxicities associated with the administration of CAR-T therapies in oncology patients","volume":"48","author":"Renninger","year":"2025","journal-title":"Drug Saf"},{"issue":"suppl 1","key":"10.1016\/j.mayocpiqo.2026.100758_bib24","doi-asserted-by":"crossref","first-page":"7246","DOI":"10.1182\/blood-2024-210573","article-title":"Managing CAR T-cell toxicity: impact of steroid prophylaxis on toxicity and outcomes","volume":"144","author":"Upadhyay","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2026.100758_bib25","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3390\/biom13020382","article-title":"Early use of corticosteroids following CAR T-cell therapy correlates with reduced risk of high-grade CRS without negative impact on neurotoxicity or treatment outcome","volume":"13","author":"Lakomy","year":"2023","journal-title":"Biomolecules"},{"issue":"suppl 1","key":"10.1016\/j.mayocpiqo.2026.100758_bib26","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1182\/blood-2023-185632","article-title":"Invasive fungal infections after CAR T-cell therapy for B-cell lymphoma: a study from the French Descart registry","volume":"142","author":"Bouvier","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2026.100758_bib27","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jtct.2024.10.010","article-title":"Shift from widespread to tailored antifungal prophylaxis in lymphoma patients treated with CD19 CAR T cell therapy: results from a large retrospective cohort","volume":"31","author":"Melica","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.mayocpiqo.2026.100758_bib28","series-title":"The EBMT\/EHA CAR-T Cell Handbook","first-page":"141","article-title":"Management of immune effector cell-associated neurotoxicity syndrome (ICANS)","author":"Rees","year":"2022"},{"issue":"suppl 1","key":"10.1016\/j.mayocpiqo.2026.100758_bib29","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1182\/blood-2025-127","article-title":"Comparison of axi-cel versus liso-cel as 2nd line therapy for relapsed\/refractory large B-cell lymphoma in real-life: a lysa study from the descar-T registry","volume":"146","author":"Brisou","year":"2025","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.mayocpiqo.2026.100758_bib30","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"}],"container-title":["Mayo Clinic Proceedings: Innovations, Quality &amp; Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542454826000652?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542454826000652?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:54:33Z","timestamp":1792788873000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2542454826000652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2542454826000652"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocpiqo.2026.100758","relation":{},"ISSN":["2542-4548"],"issn-type":[{"value":"2542-4548","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety Profile of Chimeric Antigen Receptor T-cell Therapies in Diffuse Large B-cell Lymphoma: An Analysis of Real-World Adverse Event Reporting From the FDA Adverse Event Reporting System","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings: Innovations, Quality & Outcomes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocpiqo.2026.100758","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc on behalf of Mayo Foundation for Medical Education and Research.","name":"copyright","label":"Copyright"}],"article-number":"100758"}}